Company Overview and News

0
FCAP / First Capital, Inc. 8-K (Current Report)

2018-07-17 sec.gov
UNITED STATES
FCAP

3
GAZIT GLOBE (GZT):  A Quality Global Shopping Center REIT That Is Reasonably Priced

2018-07-17 seekingalpha
This REIT sells at about 55% of its fair value while paying a 4.5% dividend yield.
REG FCR.DB.H REG.PRG FCR.DB.I REG.PRF FCR.DB.J GZT DTK EQIT FCRGF GZT FRT FCAP FCR FCR.DB.E EQY

0
First Capital downgrades exchange rate target to 161 rupees for end 2018

2018-07-11 lankabusinessonline
July 11, 2018 (LBO) – First Capital Research said they downgraded their exchange rate target from 159 rupees to 161 rupees per dollar for end 2018 since a stronger dollar is more likely in the coming months.
FCAP

61
10 Best Stocks Under $10

2018-07-11 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I WETF BXG VAC FCR.DB.J AY DXJ FSC GZT OAK HEDJ OSLE JILL SIRI ARCO AMZN OAK.PRA FCR.DB.E MCD REG.PRG REG.PRF BBX IBN AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

0
First Capital Realty Announces New Investments in Core Urban Markets and $200 Million Bought Deal Equity Offering

2018-07-09 globenewswire
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- First Capital Realty Inc. (“First Capital” or the “Company”) (TSX:FCR), one of Canada’s largest owners, developers and managers of grocery anchored, retail-focused urban properties, announced today that it has acquired or entered into agreements to acquire several high quality properties in core urban markets in Canada (collectively the “Acquisition Properties”) and that it has commenced the development of two currently owned assets (collectively the “Development Assets”) which represent an aggregate capital requirement of approximately $300 million at the Company’s share.
CHOO FCR.DB.H FCR.DB.I FCRGF FCR.DB.J FCAP JYMHF FCR FCR.DB.E

133
10 Best Stocks Under $10

2018-06-19 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I FXFLF WETF BXG VAC FXFHF FAXXF FCR.DB.J AY DXJ FSC GZT OAK HEDJ FRFHF OSLE FRFFF JILL SIRI ARCO AMZN OAK.PRA FRFZF FAXRF FRFXF FCR.DB.E MCD REG.PRG REG.PRF BBX IBN FRFGF AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

0
We need to fix up 17th Avenue, but we'd better not screw it up

2018-06-09 cbc.ca
This strip of asphalt lined with shops, bars, coffee shops, a couple empty lots, apartments and condos, runs the gamut from shabby to chic. It's arguably the heart of our city, a key social node — and our place to be.
CDNTF CDNAF FCAP

0
First Capital records highest ever PAT of Rs. 1.96 billion in 17/18

2018-05-31 lankabusinessonline
First Capital Holdings PLC (The Group) the only listed investment bank in Sri Lanka, recorded its highest ever Consolidated Profit after Tax of Rs 1,960Mn for the year 2017/18, marking a milestone in the investment bank’s history. The results show a significant growth compared to Rs. 232Mn in 2016/17. First Capital, with its impressive 35 year history, has total assets of Rs.35Bn and Equity in excess of Rs.
CFVF FCAP

3
Gazit-Globe Ltd. (GZT) CEO Chaim Katzman on Q1 2018 Results - Earnings Call Transcript

2018-05-29 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Gazit-Globe First Quarter 2018 Results Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by question-and-answer session. I advise you that this conference is being recorded today, Tuesday, May 29, 2018. The presentation that will be used in today's call and the financial statements can be found on Gazit-Globe's Web site at www.
FCAP URBN EQIT EQY

3
Gazit-Globe Reports Strong Operational Results in First Quarter 2018

2018-05-28 globenewswire
TEL AVIV, Israel, May 28, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced today its financial results for the first quarter ended March 31, 2018.
REG FCR.DB.H REG.PRG FCR.DB.I REG.PRF FCR.DB.J GZT DTK FCRGF GZT FCAP FCR FCR.DB.E

2
FCAP / First Capital, Inc. 8-K (Current Report)

2018-05-25 sec.gov
UNITED STATES
FCAP

0
Esports Entertainment Group Announces $600,000 Financing With First Capital Ventures 

2018-05-17 globenewswire
ST. MARY'S, Antigua, May 17, 2018 (GLOBE NEWSWIRE) -- Esports Entertainment Group, Inc. (OTCQB:GMBL) (or the "Company"), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, is pleased to announced financing in the amount of $600,000 with Denver, CO-based First Capital Ventures (“First Capital”), which first provided the Company with financing of $600,000 in March 2017.
FCAP

1
FCAP / First Capital, Inc. FORM 10-Q (Quarterly Report)

2018-05-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One)
FCAP

0
First Capital, Inc. Reports Quarterly Earnings Increase

2018-04-27 globenewswire
CORYDON, Ind., April 27, 2018 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ:FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $2.1 million or $0.64 per diluted share for the quarter ended March 31, 2018, compared to $1.6 million or $0.46 per diluted share for the quarter ended March 31, 2017. The increase in net income is primarily due an increase in net interest income after provision for loan losses and a decrease in income tax expense.
FCAP

0
FCAP / First Capital, Inc. FORM 8-K (Current Report)

2018-04-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
FCAP

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 31942S104